Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Mission Bio Blog and Podcast go live! Get the latest news and trends on single-cell multi-omics. Subscribe

A neural crest stem cell-like state drives nongenetic resistance to targeted therapy in melanoma

Marin-Bejar, O. et al.

The ability to predict the future behaviour of an individual cancer is crucial for precision cancer medicine and, in particular, for the development of strategies that prevent acquisition of resistance to anti-cancer drugs. Therapy resistance, which often develops from a heterogeneous pool of drug-tolerant cells known as minimal residual disease (MRD), is thought to mainly occur through acquisition of genetic alterations. Increasing evidence, however, indicates that drug resistance might also be acquired though nongenetic mechanisms. A key emerging question is therefore whether specific molecular and/or cellular features of the MRD ecosystem determine which of these two distinct resistance trajectories will eventually prevail.




Marin-Bejar, O., Rogiers, A., Dewaele, M., Femel, J., Karras, P., Pozniak, J., Bervoets, G., Raemdonck, N.V., Pedri, D., Swings, T., Demeulemeester, J., Borght, S.V., Bosisio, F.,  van den Oord, J.J., Bempt, I.V., Lambrechts, D., Voet, T., Bechter, O.,  Rizos, H., Levesque, M., Leucci, E., Lund, A.W., Rambow, F., Marine, J.C.


Personalized single-cell proteogenomics to distinguish acute myeloid leukemia from nonmalignant clonal hematopoiesis
Dillon, L.W.
Blood Cancer Discovery
PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism
Ren, A.A.
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
Wang, F.
Nature Communications
Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing
Lim, K.
Blood Advances